IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today ...

Enamel, the hardest and most mineralized substance in the body, covers the outer layer of each tooth. It's the first defense ...

Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today announced that the company will release ...

PatchMD, a leader in innovative nutrient delivery systems, proudly announces the launch of its new Mito Cocktail Patch, ...

OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it was selected as one of the ...

NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer’s ...

Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, March 24, 2025 (GLOBE ...

BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025 BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), ...

As of December 31, 2024, Aura had cash and cash equivalents and marketable securities totaling $151.1 million. The Company believes its current cash and cash equivalents and marketable securities are ...

On July 21, 2023, AEON completed the Merger with AEON Biopharma Sub, Inc. (“Old AEON”), with Old AEON surviving the merger as a wholly-owned subsidiary of the Company, the accounting acquirer. The ...

Fourth Quarter and Full Year 2024 Financial Results Conference Call Date: March 24, 2025 Time: 4:30 p.m. ET Live Call: 1-800-245-3047 (U.S. Toll Free) or 1-203-518-9765 (International) Webcast: Events ...

Net Loss: The net loss attributable to Serina for the year ended December 31, 2024 was $11.1 million, or $ (1.51) per basic and diluted share, compared to net income of $5.3 million, or $2.36 per ...